An orange immunoglobulin protein structure with blue and purple antibodies attached protrudes from a light purple lipid bilayer against a pink, blue, and black background

istock-1397970801

Charles River

Detecting drug-protein interactions early helps researchers improve candidate selection.&nbsp;

Understanding the implications of off-target binding for drug safety and development

Ebooks

Drs. Ulrike Herbrand, Christopher Sucato and Alvaro Jorge Amor of Charles River Laboratories discuss the challenges of bringing antibody-drug conjugates to market

Guest Commentary: A tale of safety and consistency

Articles

1-0325-cover

March 2025

Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.

article

Diagram showing how patient-derived somatic cells are reprogrammed into iPSCs using Yamanaka factors and then differentiated into specialized cell types such as neurons, cardiomyocytes, and hepatocytes.

ips-cells-image

BPS Bioscience

Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.

Improving translational research with iPSC-derived cells

mike-heaven-phd

Characterizing lipid nanoparticles for RNA therapeutic development

205c4df9-5f8b-4936-b768-3f926ab08bbc

Inotiv

Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.

Characterizing<strong id="isPasted">&nbsp;</strong>lipid nanoparticles for RNA therapeutic development

Webinars

A molecular structure of protein is shown as a swirled structure of blue, orange, and pink strands against a black background.

istock-1225652892-1800x900

 A molecular structure of protein is shown as a swirled structure of blue, orange, and pink strands against a black background.

Thermo Fisher Scientific

Advanced techniques, tools, and strategies can help researchers refine their proteomics workflows, improving downstream results.

Charles River

Content by Charles River

Understanding the implications of off-target binding for drug safety and development

Guest Commentary: A tale of safety and consistency

Subscribe to our eNewsletters

Sponsored

March 2025